Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / May / Blanket Coverage
Retina Research & Innovations Neuro-ophthalmology

Blanket Coverage

A single gene target may be the way forward for combating retinal degeneration

By Geoffrey Potjewyd 5/11/2022 1 min read

Share

We are constantly learning more about genetic contributions to eye conditions – through both advancements in technology and work in the lab. But is the genetic information we uncover about diseases useful if many genes contribute to a single condition? Developing a therapeutic for one genetic contributor may help, but it may also result in a one-dimensional and potentially ineffective treatment for a disease that is multifaceted and multifactorial.

Researchers from Trinity School of Genetics and Microbiology in Dublin, Ireland, may have found a single gene target with a blanket coverage effect on treating impaired vision – and perhaps even blindness. The SARM1 gene has been shown to drive the process of retinal ganglion cell (RGC) degeneration of and ultimately causes visual impairment and blindness (1). Suppressing SARM1 in a mouse model protected spatial vision, increased RGC survival, and preserved axonal density in the optic nerves for four months. In essence, the group found that, by suppressing SARM1, they were able to combat mitochondrial dysfunction – a hallmark contributor to many ocular and neurodegenerative diseases – in the retina at a tissue level and at a functional level.

Although this research is promising, there is quite a way to go before therapeutics can be made available. Nonetheless, the work offers hope that we may one day be able to treat diseases that affect the optic nerve, such as glaucoma. Aside from the ocular applications, the positive effect of SARM1 suppression also stretches to neuronal cells (2) – meaning that the gene may be a viable target for neurodegenerative diseases, such as Alzheimer’s disease, that are characterized by mitochondrial dysfunction.

References

  1. LK Finnegan et al., Int J Mol Sci, 23, 1606 (2022). PMID: 35163535.
  2. GJ Farrar et al., Trends Genet, 29, 488 (2013). PMID: 23756086.

About the Author(s)

Geoffrey Potjewyd

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

More Articles by Geoffrey Potjewyd

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: